Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
Sponsor: University of Rochester
Summary
This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.
Official title: A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-02-20
Completion Date
2028-01-01
Last Updated
2026-01-13
Healthy Volunteers
No
Interventions
Lisinopril Tablets
This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.
Locations (1)
Wilmot Cancer Institute
Rochester, New York, United States